文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

TLR8功能获得性突变患者的临床特征、管理及造血细胞移植

Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.
PubMed 文献 · Blood Adv · 2026-01-01

本文报告了10例TLR8功能获得性(GOF)患者的扩展临床与实验室表型及管理,包括首例女性患者(婴儿期起病,纯红细胞再生障碍,生殖系TLR8变异)和2个新的男性致病性体细胞变异。所有患者均有中性粒细胞减少,7例行异基因造血细胞移植(HCT),5例存活1-3年且供者嵌合完全、疾病表型消退;未行HCT的2例儿童患者最终死于疾病。TLR8 GOF为X连锁显性疾病,对内科治疗难治,应考虑早期行异基因HCT。

要点

  • TLR8 GOF应纳入男性和女性血细胞减少、尤其严重中性粒细胞减少伴淋巴细胞增殖和免疫失调的鉴别诊断。
  • 骨髓特征为严重髓系发育低下和活化T细胞浸润和/或聚集,部分患者外周血大颗粒淋巴细胞增多。
  • 疾病对内科治疗难治,作者认为应考虑在诊断后早期行治愈性异基因HCT。

核心结论

  • TLR8 GOF是X连锁显性疾病,对内科治疗难治,作者认为应考虑在诊断后早期行治愈性异基因HCT。

研究设计与样本

  • 本文报告10例TLR8 GOF患者的扩展临床与实验室表型及管理,包括原始队列的6例男性患者。
  • 研究纳入首例女性TLR8 GOF患者(婴儿期起病,纯红细胞再生障碍,生殖系TLR8变异)和2例男性患者的新致病性体细胞变异。
  • 该试验在www.clinicaltrials.gov注册,注册号为#NCT04339777。

主要发现

  • 8例患者存在体细胞嵌合,外周血变异等位基因频率为7%至26%,发病年龄为9个月至28岁。
  • 所有患者均有中性粒细胞减少,其中大多数为对内科治疗难治的严重中性粒细胞减少;贫血和血小板减少常见。
  • 骨髓特征性表现为严重髓系发育低下和活化T细胞浸润和/或聚集;5例患者发现大颗粒淋巴细胞(LGL)数量增多。
  • 7例患者接受异基因造血细胞移植(HCT),观察到高发生率的移植后原因不明的血细胞减少和移植物抗宿主病。
  • 5例患者在HCT后1至3年存活,供者髓系和T细胞嵌合完全,疾病表型消退;2例儿童期起病且未行HCT的患者最终死于疾病。

临床怎么用

  • 作者认为,TLR8 GOF应考虑到男性和女性血细胞减少患者中,尤其是严重中性粒细胞减少、淋巴细胞增殖伴免疫失调、LGL增多以及本队列新增的红细胞再生障碍。
  • 作者认为,疾病对内科治疗难治,应考虑在诊断后早期行治愈性异基因HCT。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Toll-like receptor 8 (TLR8) gain-of-function (GOF) somatic variants were recently identified as causing severe neutropenia, lymphoproliferation, and immune dysregulation. We report the expanded clinical and laboratory phenotype and management of 10 patients, including the original cohort of 6 male patients. We identify the first female patient with TLR8 GOF who presented during infancy with pure red cell aplasia due to a germ line TLR8 variant, and 2 new disease-causing somatic variants in male patients. Eight patients had somatic mosaicism with peripheral blood variant allele fractions of 7% to 26%, and age of disease onset of 9 months to 28 years. All patients had neutropenia, most with severe neutropenia refractory to medical therapy. Anemia and thrombocytopenia were common. Bone marrow characteristically demonstrated severe myeloid hypoplasia and activated T-cell infiltrates and/or aggregates. An increased number of large granular lymphocytes (LGLs) was identified in 5 patients. Seven patients underwent allogeneic hematopoietic cell transplant (HCT). High rates of post-HCT cytopenia of unclear etiology and graft-versus-host disease were observed. Five patients are surviving at 1 to 3 years after HCT with full donor myeloid and T-cell chimerism, and resolution of disease phenotype. The 2 patients who presented during childhood and did not undergo HCT ultimately died from disease. In conclusion, TLR8 GOF is an X-linked dominant disorder that should be considered in male and female patients with cytopenia, particularly severe neutropenia, lymphoproliferation with immune dysregulation, increased LGLs, and new to this cohort, red cell aplasia. Disease is refractory to medical management, and curative, allogeneic HCT should be considered early after diagnosis. This trial was registered at www.clinicaltrials.gov as #NCT04339777.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Arnold DE, Kaviany S, Aluri J, et al. Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function. Blood Adv. 2026. PMID: 41370196. doi:10.1182/bloodadvances.2025016338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。